Abeona Therapeutics Inc. (LON:0H7R)

Market Cap	200.97M +6.3%
Revenue (ttm)	297.58K
Net Income	61.26M
EPS	0.96
Shares Out	n/a
PE Ratio	3.28
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267
Average Volume	7,655
Open	5.200
Previous Close	5.030
Day's Range	4.950 - 5.200
52-Week Range	3.840 - 7.500
Beta	1.13
RSI	46.38
Earnings Date	Mar 20, 2026

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform progra...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1974
• Employees: 136
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H7R

Financial Performance

Financial numbers in USD